Ferring featured in the American Medical Review ™ television series
Copenhagen, Denmark – March 18, 2003 –
Ferring will be featured on the television programme American Medical Review this spring Season on American Public Television.
The series, hosted by Morley Safer (60 Minutes) features stories on various technologies, products or services that have significantly contributed on an international level to the advancement of the healthcare industry.
The 5-minute segment features interviews with Ferring Research Institute (FRI), Vice-President Jerzy Trojnar and Board Director, Prof. Michael Rosenblatt. Infertility specialist, Dr. William P. Hummel of the San Diego Fertility Center was also interviewed.
Ferring’s history and unique qualifications in peptide research is highlighted in the segment along with information regarding Ferring’s new compounds in prostate cancer and urology. The programme begins with information on the company’s specialisation in natural-derived infertility products and then broadly turns to the Ferring’s milestones made in peptide research and drug development. The show ends with an interview with Dr. Trojnar and Prof. Rosenblatt describing the numerous research possibilities in the field of peptides especially in osteoporosis.
‘We are extremely proud that the American Medical Review chose Ferring as a topic for their show. Peptides are our strong point and it is fantastic to be recognised on public television for our efforts,’ said Dr. Trojnar.
Portions of the Ferring profile were shot on location at FRI in San Diego, California and Harvard Medical School in Boston, Mass. This profile will be fed via satellite to 345 Public Television stations nationally in the US. The individual stations based on their own varying schedules – primarily during peak and prime time programming, air American Review Series profiles.
The American Review Series profiles can also be seen on the American Independent Network, AIN, as well as internationally on WorldNet, a U.S. Government News and Information service.
About Ferring Pharmaceuticals
Ferring is a research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology.
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.
To learn more about Ferring or our products please visit us at www.Ferring.com.
For more information, please contact
Sharmi Albrechtsen
Ferring International Center
+45 28 78 72 09
sharmi.albrechtsen@ferring.com